Wedbush analyst Yun Zhong lowered the firm’s price target on Sarepta (SRPT) to $29 from $34 and keeps an Outperform rating on the shares. The firm says the Q4 revenue provided no surprises after the pre-announcement in January, but management’s 2026 revenue guidance was likely below the Street’s expectations. Wedbush’s optimism in both Elevidys and PMO products is unchanged, but the firm has adjusted its revenue projection based on the above guidance.
Claim 55% Off TipRanks
Trade SRPT with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target lowered to $38 from $45 at Wells Fargo
- Sarepta price target lowered to $20 from $22 at Baird
- Sarepta downside risks outweigh upside potential, says Citi
- Cut Guidance, Clinical Uncertainty, and PMO Franchise Risk Underscore Negative Risk–Reward for Sarepta
- Maintaining Hold on Sarepta: Weaker Elevidys Outlook, Competitive PMO Pressures, and CEO Transition Temper Near‑Term Upside